Literature DB >> 6385761

Diagnostic value of serum procollagen peptide measurements in alcoholic liver disease.

E R Savolainen, B Goldberg, M A Leo, M Velez, C S Lieber.   

Abstract

Procollagen type I carboxyterminal and type III aminoterminal peptide concentrations were measured in sera of 60 patients with alcoholic and 14 with nonalcoholic liver disease to study whether these assays are useful as clinical tests to differentiate various stages of alcoholic liver injury. Both propeptides were markedly elevated in alcoholic hepatitis and cirrhosis: procollagen type III peptide in 90% and type I peptide in 60-80% of these patients. Moderately increased values were found less frequently in patients with fatty liver. These tests did not differentiate patients with simple fatty liver from those with fatty liver and early fibrosis. There was a significant difference in serum procollagen type III peptide between fatty liver and both alcoholic hepatitis and cirrhosis (p less than 0.001), and in type I peptide between fatty liver and alcoholic hepatitis (p less than 0.005). Although serum peptide values correlated with the degree of liver fibrosis, appreciable overlap of values was found between the various groups. The peptide concentrations also seemed to be related to the degree of hepatic inflammation, and the highest values were observed in a subgroup of patients with alcoholic hepatitis in whom numerous Mallory bodies were found. The data suggest that in alcoholic liver diseases, serum collagen propeptide determination may be useful in diagnosing severe alcoholic hepatitis.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6385761     DOI: 10.1111/j.1530-0277.1984.tb05684.x

Source DB:  PubMed          Journal:  Alcohol Clin Exp Res        ISSN: 0145-6008            Impact factor:   3.455


  9 in total

1.  Type I and type III procollagen peptides during hepatic fibrogenesis. An immunohistochemical and ELISA serum study in the CCl4 rat model.

Authors:  B H Davis; J A Madri
Journal:  Am J Pathol       Date:  1987-01       Impact factor: 4.307

2.  Prolonged exercise causes an increase in the activity of galactosylhydroxylysyl glucosyltransferase and in the concentration of type III procollagen aminopropeptide in human serum.

Authors:  T E Takala; J Vuori; H Anttinen; K Väänänen; R Myllylä
Journal:  Pflugers Arch       Date:  1986-11       Impact factor: 3.657

3.  An immunohistochemical and serum ELISA study of type I and III procollagen aminopropeptides in primary biliary cirrhosis.

Authors:  B H Davis; J A Madri
Journal:  Am J Pathol       Date:  1987-08       Impact factor: 4.307

4.  Effects of malotilate treatment on the serum markers of hepatic fibrogenesis in liver cirrhosis.

Authors:  S Takase; A Takada; M Yasuhara; H Sato; Y Matsuda
Journal:  Gastroenterol Jpn       Date:  1988-12

5.  Serum carboxy terminal propeptide of type I procollagen to amino terminal propeptide of type III procollagen ratio is a better indicator than each single propeptide and 7S domain type IV collagen for progressive fibrogenesis in chronic viral liver diseases.

Authors:  D Y Lin; C M Chu; I S Sheen; Y F Liaw
Journal:  Dig Dis Sci       Date:  1995-01       Impact factor: 3.199

6.  Biochemical evidence of myocardial fibrosis in veteran endurance athletes.

Authors:  M Mitchell Lindsay; Francis G Dunn
Journal:  Br J Sports Med       Date:  2007-02-20       Impact factor: 13.800

7.  Ultrastructural localization of type III procollagen in baboon liver.

Authors:  S Sato; M A Leo; C S Lieber
Journal:  Am J Pathol       Date:  1986-02       Impact factor: 4.307

8.  A monoclonal antibody to the carboxyterminal domain of procollagen type I visualizes collagen-synthesizing fibroblasts. Detection of an altered fibroblast phenotype in lungs of patients with pulmonary fibrosis.

Authors:  J A McDonald; T J Broekelmann; M L Matheke; E Crouch; M Koo; C Kuhn
Journal:  J Clin Invest       Date:  1986-11       Impact factor: 14.808

9.  Clinical studies of type-I procollagen carboxyterminal peptide in serum of patients with gastric cancer: comparison with CEA and CA19-9.

Authors:  K Ogawa; Y Naritaka; T Katsube; Y Ohtani; H Yagawa; T Kajiwara
Journal:  J Gastroenterol       Date:  1994-06       Impact factor: 7.527

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.